Nihan Bahadır
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Nihan Bahadır has a total of 227 co-authors. Here are the top co-authors by number of shared publications:
- Fatih Akkaya
Department of Cardiology, Faculty of Medicine Ordu University Ordu Türkiye
4 shared publications - Baver Ekinci2 shared publications
- Emirhan Çakır
Department of Cardiology, School of Medicine, Trakya University, 22030 Edirne, Turkey
2 shared publications - Emre Asiltürk
Antalya Training and Research Hospital, Antalya, Turkiye
2 shared publications - Ferit Böyük
Department of Cardiology, Kanuni Sultan Süleyman Training and Research Hospital, Health Science University, İstanbul 34303, Türkiye
2 shared publications - Mehmet Kış
Department of Cardiology, Faculty of Medicine, Dokuz Eylül University, 35340 İzmir, Turkey
2 shared publications
Latest Publications
- Open Access
- 3 October 2026
- Published by Wiley in Clinical Cardiology
- Vol. 49 (10)
Clarification of Reported Statistical Inconsistencies in a CHA2DS2‐VA Analysis of No‐Reflow After Primary Percutaneous Coronary Intervention
- 3 October 2026
- Published by Wiley in Clinical Cardiology
- Vol. 49 (10)
Open AccessClarification of Reported Statistical Inconsistencies in a CHA2DS2‐VA Analysis of No‐Reflow After Primary Percutaneous Coronary Intervention
- Open Access
- 2 September 2026
- Published by Elsevier in JACC: Case Reports
- Vol. 31 (43) , 110184
Immediate Cardioversion During Left Atrial Appendage Occlusion in Three Patients With Left Atrial Appendage Thrombus
- 2 September 2026
- Published by Elsevier in JACC: Case Reports
- Vol. 31 (43) , 110184
Open AccessImmediate Cardioversion During Left Atrial Appendage Occlusion in Three Patients With Left Atrial Appendage Thrombus
- 9 June 2026
- Published by Atatürk University, Medical Faculty in Trends in Surgical Sciences
- Vol. 5 (Advanced O) , 83-89
The Relationship Between Aortic Aneurysms, Inflammatory Markers, and ECG Parameters
Objective: Aortic aneurysms are vascular diseases that exhibit different pathophysiological features depending on their location and where inflammation plays an important role. In this study, the aim was to evaluate the relationship between electrocardiographic parameters and indices reflecting systemic inflammation in patients with ascending and abdominal aortic aneurysms.Methods: This retrospective study included 43 patients who underwent endovascular aneurysm repair (EVAR) for abdominal aortic aneurysm and 27 consecutive patients who were scheduled for surgical intervention due to ascending aortic aneurysm at a tertiary centre. Preoperative routine blood samples were analysed. Patients' NLR, PLR, and SII were calculated, and C-reactive protein, and RDW levels, along with other laboratory tests and ECG data, were recorded. The two groups were compared.Results: In this study of 70 patients, the mean age of the abdominal aortic aneurysm group (Group 2) was significantly higher than that of the ascending aortic aneurysm group (Group 1) (69.6±9.6 years vs. 59.97±11.8 years; P
- 9 June 2026
- Published by Atatürk University, Medical Faculty in Trends in Surgical Sciences
- Vol. 5 (Advanced O) , 83-89
The Relationship Between Aortic Aneurysms, Inflammatory Markers, and ECG Parameters
Objective: Aortic aneurysms are vascular diseases that exhibit different pathophysiological features depending on their location and where inflammation plays an important role. In this study, the aim was to evaluate the relationship between electrocardiographic parameters and indices reflecting systemic inflammation in patients with ascending and abdominal aortic aneurysms.Methods: This retrospective study included 43 patients who underwent endovascular aneurysm repair (EVAR) for abdominal aortic aneurysm and 27 consecutive patients who were scheduled for surgical intervention due to ascending aortic aneurysm at a tertiary centre. Preoperative routine blood samples were analysed. Patients' NLR, PLR, and SII were calculated, and C-reactive protein, and RDW levels, along with other laboratory tests and ECG data, were recorded. The two groups were compared.Results: In this study of 70 patients, the mean age of the abdominal aortic aneurysm group (Group 2) was significantly higher than that of the ascending aortic aneurysm group (Group 1) (69.6±9.6 years vs. 59.97±11.8 years; P
- Open Access
- 2 January 2026
- Published by Galenos Yayinevi in Balkan Medical Journal
- Vol. 43 (6) , 351-354
Real-World Diagnostic and Therapeutic Insights in Transthyretin Cardiac Amyloidosis: Experience from the Black Sea Region of Türkiye
- 2 January 2026
- Published by Galenos Yayinevi in Balkan Medical Journal
- Vol. 43 (6) , 351-354
Open AccessReal-World Diagnostic and Therapeutic Insights in Transthyretin Cardiac Amyloidosis: Experience from the Black Sea Region of Türkiye
- 23 June 2025
- Published by Academician Publishing
- p. 199-208
Antiphospholipid Syndrome
Antiphospholipid syndrome (APS) is an autoimmune disease that effects multisystems and organs; develops as a result of antiphospholipid antibodies (aPL) dependent with vascular thromboses and/ or pregnancy complications. Firstly in the early 1980s, APS was described based on the observation that thrombosis and pregnancy losses were seen more frequently in SLE patients who had lupus anticoagulant (LA), anti-cardiolipin antibodies. The prevalence of APS is approximately 50/100 000 of the population. The prevelance of APS increases with age; the prevelance especially high in older patients with a chronic disease. Antiphospholipid syndrome can be secondary or primary; secondary APS is associated with other autoimmune disease, particularly systemic lupus erythematosus (SLE) and primary APS is assosiated no autoimmune disease. Clinical thrombotic vascular complications are often associated with antiphospholipid antibodies that can occur autoimmune disease, viral,bacterial, protozoal, fungal infections, malignancies, drug. Patients who have antiphospholipid antibodies (aPL) are at risk of developing thrombocytopenia, venous and arterial thrombosis, and recurrent fetal loss. Thrombosis can involve both arteriel and venous systems, tend to recurrence and can occur in the same system. In the studies, thrombotic manifestations of APS is seen mostly by venous thromboembolism with approximately 60% ratio. APS is a syndrome has multisystemic involvement due to acquired hypercoagulable state and associated with various thrombotic and nonthrombotic cardiac manifestations. The cardiac involvement in APS patients is seen in a wide spectrum including ischemic heart disease, right or left ventricular dysfunction, pulmonary hypertension, intracardiac thrombosis and endomyocardial fibrosis due to thrombosis in the coronary or microvascular circulation.The most common form of cardiac involvement in APS is heart valve disease. Primary and secondary cardiovascular prevention strategies should be implemented basically with lifestyle changes firstly and involved specific treatment algorithm of cardiovascular risk factors.
- 23 June 2025
- Published by Academician Publishing
- p. 199-208
Antiphospholipid Syndrome
Antiphospholipid syndrome (APS) is an autoimmune disease that effects multisystems and organs; develops as a result of antiphospholipid antibodies (aPL) dependent with vascular thromboses and/ or pregnancy complications. Firstly in the early 1980s, APS was described based on the observation that thrombosis and pregnancy losses were seen more frequently in SLE patients who had lupus anticoagulant (LA), anti-cardiolipin antibodies. The prevalence of APS is approximately 50/100 000 of the population. The prevelance of APS increases with age; the prevelance especially high in older patients with a chronic disease. Antiphospholipid syndrome can be secondary or primary; secondary APS is associated with other autoimmune disease, particularly systemic lupus erythematosus (SLE) and primary APS is assosiated no autoimmune disease. Clinical thrombotic vascular complications are often associated with antiphospholipid antibodies that can occur autoimmune disease, viral,bacterial, protozoal, fungal infections, malignancies, drug. Patients who have antiphospholipid antibodies (aPL) are at risk of developing thrombocytopenia, venous and arterial thrombosis, and recurrent fetal loss. Thrombosis can involve both arteriel and venous systems, tend to recurrence and can occur in the same system. In the studies, thrombotic manifestations of APS is seen mostly by venous thromboembolism with approximately 60% ratio. APS is a syndrome has multisystemic involvement due to acquired hypercoagulable state and associated with various thrombotic and nonthrombotic cardiac manifestations. The cardiac involvement in APS patients is seen in a wide spectrum including ischemic heart disease, right or left ventricular dysfunction, pulmonary hypertension, intracardiac thrombosis and endomyocardial fibrosis due to thrombosis in the coronary or microvascular circulation.The most common form of cardiac involvement in APS is heart valve disease. Primary and secondary cardiovascular prevention strategies should be implemented basically with lifestyle changes firstly and involved specific treatment algorithm of cardiovascular risk factors.
- 6 August 2024
- Published by Academician Publishing
- p. 239-250
Lead Ekstraksiyonu
- Open Access
- 6 August 2024
- Published by Academician Publishing
İmplante Edilebilir Kardiyak Elektronik Cihazlar
Kardiyak Pace Tipi ve Pacing Modları Gamze Yeter ARSLAN Kalıcı Kalp Pili Endikasyonları Yusuf HOŞOĞLU Ayşe HOŞOĞLU Pacemaker & ICD İmplantasyonu Yakup YİĞİT Leadless Pacemaker Yusuf Ziya ŞENER Geçici Transvenöz Pacing ve Komplikasyonları Didar Elif AKGUN Yavuz Selim AKGUN Primer Koruma Amaçlı İmplante Edilebilir Kardiyoverter Defibrilatör Tarık YILDIRIM Sekonder Profilaksi Amaçlı İmplante Edilebilir Kardiyoverter Defibrilatör Seda Elçim YILDIRIM İmplante Edilebilir Kardiyoverter-Defibrilatör Programlama Arzu YAZAR İmplante Edilebilir Kardiyoverter Defibrilatör (ICD) Mevcut Hastalarda Uygun Cihaz Şoklarının Yönetimi Neşri DANIŞMAN Şeyhmus KULAHCIOĞLU Uygunsuz İmplante Edilebilir Kardiyoverter Defibrilatör (ICD) Şokları ve Yönetimi Onur ALTINKAYA Subkutan ICD Ertan AYDIN Giyilebilir Kardiyak Defibrilatör Abdullah SARIHAN Lütfü BEKAR Genetik Testler Selahattin AKYOL Holter Ritim Monitörizasyonu Sinem ÖZBAY ÖZYILMAZ İmplante Edilebilir Loop Recorder Hatice TAŞKAN Tilt Table Testi Güney SARIOĞLU Pacemaker ve ICD Endikasyonu Belirlemede Kullanılan Testler-Kardiyak Görüntüleme (EKO ve MRG) Emirhan ÇAKIR Elektrofizyolojik Çalışma Muhammed Kemal KAHYALAR Kalp Yetersizliği Tedavisinde Kardiyak Resenkronizasyon Tedavisi Enfal ÇAKMAK AKSU Fatih AKKAYA Kardiyak Resenkronizasyon Tedavisi Endikasyonları ve Hasta Seçimi Tayfur ERDOĞDU Koroner Sinüs Anatomisi ve KRT Doğan İLİŞ KRT İmplantasyonu Kubilay ERSELCAN Cerrahi KRT İmplantasyonu Mahmut YARGI Kime KRT-D & Kime KRT-P Fahri CAKAN Kardiyak Resenkronizasyon Tedavisi Yanıt Tanımı ve İlişkili Faktörler Lütfü AŞKIN Elektrokardiyografi ve Ekokardiyografi ile Kardiyak Resenkronizasyon Tedavisi Optimizasyonu Şerif HAMİDEYİN Kardiyak Resenkronizasyon Tedavisi Programlama Fatih KÖKSAL Diyafragma Pacingi Yönetimi Emre ASİLTÜRK Atriyal Fibrilasyonda Atrioventriküler (AV) Nod Ablasyonu ve Kardiyak Resenkronizasyon Tedavisi Halil İbrahim DURMUŞ HİS-Demeti Pacing Ayça ARSLAN Sol Dal Pacing İnanç ARTAÇ HİS Optimize Kardiyak Resenkranizasyon Tedavisi Süleyman BARUTCU Sol Dal Optimize Kardiyak Resenkronizasyon Tedavisi Hakan Gökalp UZUN Jeneratör Replasmanı Yusuf Bozkurt ŞAHİN Lead Ekstraksiyonu Nihan BAHADIR Kardiyak İmplante Edilebilir Elektronik Cihazların (KİEC) İmplantasyonu Sonrası Takip Şeyhmus Erkan DEMİRCAN Baver EKİNCİ Atrial Yüksek Hız Epizot Yönetimi Muhammet GENEŞ Kardiyak İmplante Edilebilir Cihazlarda Telekardiyografik Değerlendirme Zelal TAHAOĞLU Pil Cebi Hematomu Sidar Şiyar AYDIN Pnömotoraks, Hemotoraks ve Brakiyal Pleksus Yaralanması Ali Nail KAYA Kardiyak İmplante Edilebilir Elektronik Cihazların Komplikasyonu Kardiyak Rüptür/Perikardiyal Efüzyon Burcu KODAL Lead Kusurları Mert Pehlivan ALTIN Lead Dislokasyonu Sendromları Vedat CİCEK Samet YAVUZ Lead İlişkili Triküspit Yetmezliği Timor OMAR Pacemaker Aracılı Taşikardi Lütfullah CANDAN Pacemaker Sendromu Murat KARACAM Gülümser Sevgin HALİL Oversense Sendromları Selahattin AYDIN Kardiyak İmplante Edilebilir Cihaz Enfeksiyonu Mürsel ŞAHİN Kiec İlişkili Lead Trombüsü ve Pulmoner Embolizm Emre YILMAZ Karotid Baroreseptör Stimülasyonu Fehmi ESER Ramazan DUZ Kardiyak Kontraktilite Modülasyonu Sümeyye Fatma ÖZER Pulmoner Arter Basıncı Monitorizasyonu Muammer KARAKAYALI Kardiyak İmplante Edilebilir Elektronik Cihaz İmplantasyon Sürecinde Antikoagülan Tedavi ve Antibiyotik Proflaksisi Ömer ŞİT Preoperatif Kardiyak İmplante Edilebilen Cihaz Ayarlama Ferit BÖYÜK Radyoterapi Sürecinde Kalp Pili & ICD Takibi Yusuf Ziya ŞENER Kardiyak İmplante Edilebilir Elektronik Cihazı Olan Hastada Manyetik Rezonans Görüntüleme Semih KALKAN Kalp Pili & İmplante Edilebilir Kardiyak Defibrilatör (ICD) Olan Hastalarda Spor Aktivitesi ve Sürücülük Ahmet Lütfü SERTDEMİR Ahmet Taha ŞAHİN LVAD İmplantasyonu Yapılan Hastada ICD Endikasyonu ve Yönetimi Berhan KESKİN Kardiyak Cerrahi Sonrası Pacing Muhammed Bahadır OMAR TAVİ Sonrası Pacemaker İmplantasyonu Mehmet KIŞ Çisem OKTAY Konjenital Kalp Hastalıklarında Kardiyak Pacing ve ICD Mücahit TAN Naci BABAT Sarkoidoz Kardiyak Pacing ve ICD Ercan CEĞİLLİ Pakize SUCU Kardiyak Amiloidozda Kardiyak Pacing ve ICD Onur ASLAN Hipertrofik Kardiyomiyopatide Kardiyak Pacing ve ICD Burcu OZYAZGAN Nadir Kardiyak Hastalıklarda Kardiyak Pacing ve ICD Songül USALP
- 6 August 2024
- Published by Academician Publishing
Open Accessİmplante Edilebilir Kardiyak Elektronik Cihazlar
Kardiyak Pace Tipi ve Pacing Modları Gamze Yeter ARSLAN Kalıcı Kalp Pili Endikasyonları Yusuf HOŞOĞLU Ayşe HOŞOĞLU Pacemaker & ICD İmplantasyonu Yakup YİĞİT Leadless Pacemaker Yusuf Ziya ŞENER Geçici Transvenöz Pacing ve Komplikasyonları Didar Elif AKGUN Yavuz Selim AKGUN Primer Koruma Amaçlı İmplante Edilebilir Kardiyoverter Defibrilatör Tarık YILDIRIM Sekonder Profilaksi Amaçlı İmplante Edilebilir Kardiyoverter Defibrilatör Seda Elçim YILDIRIM İmplante Edilebilir Kardiyoverter-Defibrilatör Programlama Arzu YAZAR İmplante Edilebilir Kardiyoverter Defibrilatör (ICD) Mevcut Hastalarda Uygun Cihaz Şoklarının Yönetimi Neşri DANIŞMAN Şeyhmus KULAHCIOĞLU Uygunsuz İmplante Edilebilir Kardiyoverter Defibrilatör (ICD) Şokları ve Yönetimi Onur ALTINKAYA Subkutan ICD Ertan AYDIN Giyilebilir Kardiyak Defibrilatör Abdullah SARIHAN Lütfü BEKAR Genetik Testler Selahattin AKYOL Holter Ritim Monitörizasyonu Sinem ÖZBAY ÖZYILMAZ İmplante Edilebilir Loop Recorder Hatice TAŞKAN Tilt Table Testi Güney SARIOĞLU Pacemaker ve ICD Endikasyonu Belirlemede Kullanılan Testler-Kardiyak Görüntüleme (EKO ve MRG) Emirhan ÇAKIR Elektrofizyolojik Çalışma Muhammed Kemal KAHYALAR Kalp Yetersizliği Tedavisinde Kardiyak Resenkronizasyon Tedavisi Enfal ÇAKMAK AKSU Fatih AKKAYA Kardiyak Resenkronizasyon Tedavisi Endikasyonları ve Hasta Seçimi Tayfur ERDOĞDU Koroner Sinüs Anatomisi ve KRT Doğan İLİŞ KRT İmplantasyonu Kubilay ERSELCAN Cerrahi KRT İmplantasyonu Mahmut YARGI Kime KRT-D & Kime KRT-P Fahri CAKAN Kardiyak Resenkronizasyon Tedavisi Yanıt Tanımı ve İlişkili Faktörler Lütfü AŞKIN Elektrokardiyografi ve Ekokardiyografi ile Kardiyak Resenkronizasyon Tedavisi Optimizasyonu Şerif HAMİDEYİN Kardiyak Resenkronizasyon Tedavisi Programlama Fatih KÖKSAL Diyafragma Pacingi Yönetimi Emre ASİLTÜRK Atriyal Fibrilasyonda Atrioventriküler (AV) Nod Ablasyonu ve Kardiyak Resenkronizasyon Tedavisi Halil İbrahim DURMUŞ HİS-Demeti Pacing Ayça ARSLAN Sol Dal Pacing İnanç ARTAÇ HİS Optimize Kardiyak Resenkranizasyon Tedavisi Süleyman BARUTCU Sol Dal Optimize Kardiyak Resenkronizasyon Tedavisi Hakan Gökalp UZUN Jeneratör Replasmanı Yusuf Bozkurt ŞAHİN Lead Ekstraksiyonu Nihan BAHADIR Kardiyak İmplante Edilebilir Elektronik Cihazların (KİEC) İmplantasyonu Sonrası Takip Şeyhmus Erkan DEMİRCAN Baver EKİNCİ Atrial Yüksek Hız Epizot Yönetimi Muhammet GENEŞ Kardiyak İmplante Edilebilir Cihazlarda Telekardiyografik Değerlendirme Zelal TAHAOĞLU Pil Cebi Hematomu Sidar Şiyar AYDIN Pnömotoraks, Hemotoraks ve Brakiyal Pleksus Yaralanması Ali Nail KAYA Kardiyak İmplante Edilebilir Elektronik Cihazların Komplikasyonu Kardiyak Rüptür/Perikardiyal Efüzyon Burcu KODAL Lead Kusurları Mert Pehlivan ALTIN Lead Dislokasyonu Sendromları Vedat CİCEK Samet YAVUZ Lead İlişkili Triküspit Yetmezliği Timor OMAR Pacemaker Aracılı Taşikardi Lütfullah CANDAN Pacemaker Sendromu Murat KARACAM Gülümser Sevgin HALİL Oversense Sendromları Selahattin AYDIN Kardiyak İmplante Edilebilir Cihaz Enfeksiyonu Mürsel ŞAHİN Kiec İlişkili Lead Trombüsü ve Pulmoner Embolizm Emre YILMAZ Karotid Baroreseptör Stimülasyonu Fehmi ESER Ramazan DUZ Kardiyak Kontraktilite Modülasyonu Sümeyye Fatma ÖZER Pulmoner Arter Basıncı Monitorizasyonu Muammer KARAKAYALI Kardiyak İmplante Edilebilir Elektronik Cihaz İmplantasyon Sürecinde Antikoagülan Tedavi ve Antibiyotik Proflaksisi Ömer ŞİT Preoperatif Kardiyak İmplante Edilebilen Cihaz Ayarlama Ferit BÖYÜK Radyoterapi Sürecinde Kalp Pili & ICD Takibi Yusuf Ziya ŞENER Kardiyak İmplante Edilebilir Elektronik Cihazı Olan Hastada Manyetik Rezonans Görüntüleme Semih KALKAN Kalp Pili & İmplante Edilebilir Kardiyak Defibrilatör (ICD) Olan Hastalarda Spor Aktivitesi ve Sürücülük Ahmet Lütfü SERTDEMİR Ahmet Taha ŞAHİN LVAD İmplantasyonu Yapılan Hastada ICD Endikasyonu ve Yönetimi Berhan KESKİN Kardiyak Cerrahi Sonrası Pacing Muhammed Bahadır OMAR TAVİ Sonrası Pacemaker İmplantasyonu Mehmet KIŞ Çisem OKTAY Konjenital Kalp Hastalıklarında Kardiyak Pacing ve ICD Mücahit TAN Naci BABAT Sarkoidoz Kardiyak Pacing ve ICD Ercan CEĞİLLİ Pakize SUCU Kardiyak Amiloidozda Kardiyak Pacing ve ICD Onur ASLAN Hipertrofik Kardiyomiyopatide Kardiyak Pacing ve ICD Burcu OZYAZGAN Nadir Kardiyak Hastalıklarda Kardiyak Pacing ve ICD Songül USALP